Protection of the Ischemic Myocardium by the Converting-Enzyme Inhibitor Zofenopril: Insight Into Its Mechanism of Action

Ferrari, Roberto; Cargnoni, Anna; Curello, Salvatore; Ceconi, Claudio; Boraso, Antonella; Visioli, O

doi:10.1097/00005344-199211000-00003

Cited by 18 publications

(23 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Isolated rat hearts were perfused with KrebsHenseleit solution containing different concentrations of the ACE inhibitors (15). As shown in Fig.…”

Section: Tissue Ace Inhibitionmentioning

confidence: 99%

“…Ferrari et al (15) investigated the effects of zofenopril and captopril (both at 1 M) on the functional and metabolic damage induced by ischemia and reperfusion in isolated rabbit hearts (Fig. 4).…”

Section: In Vitro Studiesmentioning

confidence: 99%

“…The occlusion can be permanent, transient ‫51ס(‬ min; models of "stunned myocardium"), or prolonged (models of subendocardial necrosis). We shall not attempt, therefore, a discussion of cardioprotective action by ACE inhibitors in general, and will restrict the discussion to the global ischemia model (isolated rat heart), which was used to study the mechanism of cardioprotective action of zofenopril (15,17,34).…”

Section: Mechanism Of Actionmentioning

confidence: 99%

See 2 more Smart Citations

Preclinical Profile of Zofenopril: An Angiotensin Converting Enzyme Inhibitor with Peculiar Cardioprotective Properties

Subissi

Evangelista

Giachetti

1999

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

“…Isolated rat hearts were perfused with KrebsHenseleit solution containing different concentrations of the ACE inhibitors (15). As shown in Fig.…”

Section: Tissue Ace Inhibitionmentioning

confidence: 99%

Section: In Vitro Studiesmentioning

confidence: 99%

Section: Mechanism Of Actionmentioning

confidence: 99%

See 1 more Smart Citation

Preclinical Profile of Zofenopril: An Angiotensin Converting Enzyme Inhibitor with Peculiar Cardioprotective Properties

Subissi

Evangelista

Giachetti

1999

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

“…The cardiovascular effects of ACE inhibitors against ischemia and reperfusion are complex, documented by experimental studies, and include reduction in infarct size in some but not all studies [27][28][29][30][31][32][33][34][35], an improvement in intracellular biochemical homeostasis [36,37], a beneficial effect on the stunned myocardium [28,33,34] and on reperfusion arrhythmias [38][39][40], and, possibly (but still very controversial) an antioxidant action [36,37,41,42]. All of these effects have been obtained in experimental animal preparations.…”

Section: Cardioprotective Effect Of Ace Inhibitors Against Myocardialmentioning

confidence: 99%

“…Inhibition of this effect may potentially account for the cardiac protection and reduction in cardiovascular events [36,37]. The importance of this mechanism in humans is still controversial.…”

Section: Modulation Of the Sympathetic Activitymentioning

confidence: 99%

Cardioprotective effect of angiotensin-converting enzyme inhibitors in patients with coronary artery disease

Ferrari

Ceconi

Curello

et al. 1996

Cardiovasc Drug Ther

View full text Add to dashboard Cite

Clinical and experiments study with angiotensin-converting enzyme (ACE) inhibitors suggest that these agents may improve coronary artery disease by acting at multiple sites in the series of events leading to end-stage heart disease. These agents reduce blood pressure, improve prognosis and symptoms in patients with severe heart failure and in patients after acute myocardial infarction with left ventricular dysfunction. They are useful in the early, acute phase of myocardial infarction. More recently, ACE inhibitors have been shown to reduce in vitro vascular hypertrophy, to attenuate arteriosclerosis, and to maintain endothelium function. Whether these effects occur at clinical levels is still uncertain. The exciting clinical data have led to the proposal that alteration of ACE activity, particularly in tissue, is an important factor in development and progression of CAD. The ACE system is complex, with endocrine, paracrine, and autocrine effects. ACE is present in cardiac and vascular tissue. Therefore, the beneficial effects of ACE inhibitors can be classified as "cardio" and "vasculo" protective. This article summarizes a number of independent and complementary mechanisms pointing to a role of ACE and ACE inhibition in coronary artery disease.

show abstract

The Use of Angiotensin‐Converting Enzyme Inhibitors After Acute Myocardial Infarction

Mehra,

Wilson

1993

Pharmacotherapy

View full text Add to dashboard Cite

During and immediately after myocardial infarction (MI), many interrelated and complex processes manifest the body's attempt to minimize damage and compensate for lost cardiac function. Although these compensatory responses may provide some short‐term restoration of function, their long‐term consequences actually may increase morbidity and mortality. Several agents have established roles in the treatment of these patients, whereas others, including the angiotensin‐converting enzyme (ACE) inhibitors, have yet to be investigated thoroughly. Results of two trials investigating the role of ACE inhibition after MI seem to provide sufficient data to warrant the use of these drugs in certain patient populations. These results are promising, but further investigation is necessary to answer key questions arising from these trials.

show abstract

Protection of the Ischemic Myocardium by the Converting-Enzyme Inhibitor Zofenopril: Insight Into Its Mechanism of Action

Cited by 18 publications

References 0 publications

Preclinical Profile of Zofenopril: An Angiotensin Converting Enzyme Inhibitor with Peculiar Cardioprotective Properties

Preclinical Profile of Zofenopril: An Angiotensin Converting Enzyme Inhibitor with Peculiar Cardioprotective Properties

Cardioprotective effect of angiotensin-converting enzyme inhibitors in patients with coronary artery disease

The Use of Angiotensin‐Converting Enzyme Inhibitors After Acute Myocardial Infarction

Contact Info

Product

Resources

About